This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
by Zacks Equity Research
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +1.95% and +1.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Quest Diagnostics Ahead of Earnings?
by Zacks Equity Research
DGX is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
by Zacks Equity Research
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Paysafe and Champion Homes have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
PSFE earns Bull of the Day with deep value and rising earnings, while SKY's short surge and weak outlook land it as Bear of the Day.
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
by Zacks Equity Research
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant
by Zacks Equity Research
DGX, EHC, DVA, and PNTG are riding the outpatient healthcare shift as tech, AI, and aging demand reshape the care landscape.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
by Zacks Equity Research
DGX rides on double-digit diagnostics growth and a wave of strategic acquisitions despite rising debt and policy headwinds.
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DGX Stock Up on New Blood Test Development Deal With MD Anderson
by Zacks Equity Research
DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.
Take the Zacks Approach to Beat the Markets: Mirion Technologies, Avino Silver & Gold Mines, Quanta Services in Focus
by Santanu Roy
MIR, ASM and PWR outperform the S&P 500 after Zacks upgrades, spotlighting key stock picks in a volatile market.
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
by Moumi Mondal
The women's health market is booming, with Hologic and Quest Diagnostics leading the charge. But which one stands out more for investors today?
Quest Diagnostics (DGX) Down 1.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
by Zacks Equity Research
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Continue to Retain DGX Stock in Your Portfolio?
by Zacks Equity Research
Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.